(RTTNews) - Allurion Technologies, Inc. (ALUR) a Massachusetts-based medical device company Tuesday announced the issuance of a new U.S. patent for its advanced weight loss device to treat obesity, U.S. Patent No. 12,209,677.
This patent covers next-generation balloon technology with enhanced valve precision. Granted by the USPTO on January 15, the patent provides protection through July 2039. ALUR now holds 20 U.S. patents and 59 globally.
The Allurion Program combines the swallowable, procedure-free Allurion Gastric Balloon with the Allurion Virtual Care Suite, including a mobile app, connected scale, and healthcare provider tools. Patients typically lose 10-15 percent of their body weight and may increase muscle mass.
ALUR is currently trading at $2.695 or 8.02% lower on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
